Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS +2.23%92 Interest Coverage is 8.75 as of Mar. 2026, which is 51% below its 10-year median of 17.94. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 92/100 and a GF Value™ of ₹588.83 (Fairly Valued). The stock has 4 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 52.69% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Metropolis Healthcare's
Operating Income
for the
three
months ended in Mar. 2026 was ₹694 Mil. Metropolis Healthcare's Interest Expense for the
three
months ended in Mar. 2026 was ₹-79 Mil.
Metropolis Healthcare's interest coverage for the quarter that ended in Mar. 2026 was 8.75.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Metropolis Healthcare's Interest Coverage or its related term are showing as below:
NSE:METROPOLIS'
s Interest Coverage Range Over the Past 10 Years
Min: 7.79 Med: 17.94 Max: 358.3
Current: 10.88
NSE:METROPOLIS's Interest Coverage is ranked better than 52.69% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs NSE:METROPOLIS: 10.88
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Metropolis Healthcare Interest Coverage Related Terms
Metropolis Healthcare Interest Coverage Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:METROPOLIS vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a Interest Coverage of 8.75 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Metropolis Healthcare and its competitors. This is 51% below median its historical median of 17.94. Over the past decade, Metropolis Healthcare's Interest Coverage has ranged from 7.79 to 358.30. According to the industry distribution chart, Metropolis Healthcare ranks #44 out of 93 companies in the Medical Diagnostics & Research industry, placing it in the top 47.3%.
Is Metropolis Healthcare's Interest Coverage too high?
Metropolis Healthcare's current Interest Coverage of 8.75 is 51% below median its 10-year median of 17.94. Over the past 10 years, this metric has ranged from a low of 7.79 to a high of 358.30. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Metropolis Healthcare's value of 8.75 is 3.3% below this industry median. Based on the distribution chart, Metropolis Healthcare ranks #44 out of 93 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Metropolis Healthcare has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #44 out of 93 companies for Interest Coverage. This puts Metropolis Healthcare in the upper half of its industry. The industry median Interest Coverage is 9.05. Metropolis Healthcare's value of 8.75 is 3.3% below this benchmark. Historically, Metropolis Healthcare's own Interest Coverage has ranged from 7.79 to 358.30 over the past decade. While the company's 10-year median is 17.94 vs. the industry median of 9.05, Metropolis Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current Interest Coverage of 8.75 is 3.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current Interest Coverage is 8.75, which is 51% below median its own 10-year median of 17.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.83, compared to a current price of ₹571.65 — trading 2.9% below its estimated fair value. The current Interest Coverage is 8.75, which is 51% below median its 10-year median of 17.94 and 3.3% below the Medical Diagnostics & Research industry median of 9.05. Metropolis Healthcare's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Interest Coverage is 8.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹571.65 is trading 2.9% below its estimated GF Value™ of ₹588.83.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Interest Coverage: 8.75 (51% below median its 10-year median of 17.94)
GF Value™: ₹588.83 vs. price of ₹571.65 (2.9% below fair value)
Industry Position: 3.3% below the Medical Diagnostics & Research median (#44 of 93)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
92GF Score
Get the complete analysis for NSE:METROPOLIS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
